EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522